|
Mar 6
|
CEL-SCI Corporation Issues Letter to Shareholders
|
|
Dec 22
|
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
|
|
Dec 8
|
CVM: NICE To Have Your Support
|
|
Dec 4
|
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
|
|
Nov 20
|
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
|
|
Nov 16
|
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
|
|
Aug 11
|
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
|
|
Apr 28
|
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
|